D. Boral Capital Begins Coverage on Medicus Pharma (NASDAQ:MDCX)

Equities research analysts at D. Boral Capital started coverage on shares of Medicus Pharma (NASDAQ:MDCX) in a note issued to investors on Monday,Benzinga reports. The firm set a “buy” rating and a $14.00 price target on the stock. D. Boral Capital’s target price suggests a potential upside of 283.56% from the company’s current price.

MDCX has been the topic of a number of other research reports. Brookline Capital Management raised shares of Medicus Pharma to a “strong-buy” rating in a report on Monday, December 23rd. Maxim Group assumed coverage on shares of Medicus Pharma in a research note on Tuesday, December 17th. They issued a “buy” rating and a $10.00 price target on the stock.

Medicus Pharma Stock Performance

Medicus Pharma stock opened at $3.65 on Monday. Medicus Pharma has a 1 year low of $1.80 and a 1 year high of $6.00. The business has a 50-day simple moving average of $3.48.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.14. On average, research analysts expect that Medicus Pharma will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On Medicus Pharma

A hedge fund recently bought a new stake in Medicus Pharma stock. Interchange Capital Partners LLC acquired a new stake in shares of Medicus Pharma Ltd. (NASDAQ:MDCX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma makes up about 1.3% of Interchange Capital Partners LLC’s investment portfolio, making the stock its 15th largest position. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma as of its most recent filing with the Securities and Exchange Commission.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.